Pathophysiology and treatment of diabetic neuropathy

Diabetic Medicine

Volumn 15, Issue 2, 1998, Pages 97-112

  Dejgaard, A ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Adrenaline; Autonomic neuropathy; Central neuropathy; Diabetes mellitus; Diabetic neuropathy; Mexiletine; Nordrenaline; Pathophysiology; Treatment

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAPSAICIN; CARBAMAZEPINE; FLUPHENAZINE; GAMMA LINOLENIC ACID; LIDOCAINE; MEXILETINE; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THIOCTIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT;

AUTONOMIC NEUROPATHY; BRAIN DISEASE; CLINICAL TRIAL; DENERVATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE CLASSIFICATION; ELECTROENCEPHALOGRAM; EVOKED SOMATOSENSORY RESPONSE; HEARING TEST; HUMAN; METABOLIC REGULATION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PERIPHERAL NEUROPATHY; REVIEW; SYMPTOMATOLOGY;

AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETIC NEUROPATHIES; ELECTROPHYSIOLOGY; HUMANS; INCIDENCE; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE;

EID: 0031929278     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199802)15:2<97::AID-DIA523>3.0.CO;2-5     Document Type: Review

References (182)

1. Papaspyros NS. The History of Diabetes Mellius, 2nd edn. Stuttgart: Georg Thieme Verlag, 1964.
2. Rollo J. Cases of Diabetes Mellitus, 2nd edn. London: Dilly, 1798; 17-62.
3. Rundles RW. Diabetic neuropathy. Medicine 1945; 24: 110-160.
4. Ewing DJ, Campell IW, Clarke BF. Mortality in diabetic autonomic neuropathy. Lancet 1976; i: 601-603.
5. Hilsted J. Pathophysiology in diabetic autonomic neuropathy: cardiovascular, hormonal and metabolic studies. Diabetes 1982; 31: 730-737.
6. DCCT research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes melllitus. N Engl J Med 1993; 329: 977-986.
7. Ziegler D, Wiefels K, Dannehl K, Grie FA. Effects of one year of near-normoglycaemia on peripheral nerve function in Type 1 (insulin dependent)diabetic patients. Klin Wochenschr 1988; 66: 388-396.
8. Wan PH, Lau J, Chalmore TC. Meta-analysis of effects of intensive blood glucose control on the late diabetic complications of Type 1 diabetes. Lancet 1993; 341: 877-890.
9. Reichard P, Nilson BY, Rosenquist U. The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309.
10. Amthor KF, Dahl Jorgensen K, Berg TJ, Heier MS, Sandwik L, AagenFs O, Hansen KF. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1995; 37: 579-584.
11. Gabbay KH, Merola LO, Field RA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 1966; 151: 209-210.
12. Tomlinson DR. Aldose reductase inhibitors and the complications of diabetes mellitus. Diabetic Med 1993; 10: 214-230.
13. Greene DA, De Jesus PV Jr, Winegrad Al. Effects of insulin and dietary myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 1975; 55: 1326-1336.
14. Greene DA, Lattimer SA, Sima AF. Sorbitol, phosphoinositides, and sodium-potassium ATP-ase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
15. Horrobin DF. The role of essential fatty acid in the development of diabetic neuropathy and other complications of diabetes mellitus. Fatty Acids 1988; 3: 181-197.
16. Baynes JW. The role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
17. Dam SVP, Sweder VAB, Erkelens DW, Marx JJM, Gispen W, Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 1995; 11: 181-192.
18. Brownlee M, Cerami A. The biochemistry of the complications of diabetes mellitus. Ann Rev Biochem 1981; 50: 385-432.
19. Brownlee M, Vlassara H, Cerami A. Trapped immunogloblins of peripheral nerve myelin from patients with diabetes mellitus. Diabetes 1986; 35: 999-1003.
20. Yagihashi S, Kamiro M, Baba M, Yagihashi N, Nagai K. Effects of aminoguanidine on functional and strutural abnormalities in peripheral nerve of STZ induced diabetic rats. Diabete Metab 1992; 41: 47-52.
21. Boel E, Selmer J, Flodgaard HJ, Jensen T. Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproducts formation hold promise? J Diab Compl 1995; 9: 104-129.
22. Sensi M, Pricci F, Pugliese G, Rossi MG, Andreani D, Di Mario U. Role of advanced glycasylation end-products (AGE) in late diabetic complications. Diabetes Res Clin Prac 1995; 28: 9-17.
23. Newrick PG, Wilson AJ, Jacubowsky J, Boulton AJM, Ward J. Sural nerve oxygen tension in diabetes. Br Med J 1988; 293: 1053-1054.
24. Jacobsen J, Brimijoin S, Skau K, Sidenius P, Wells D. Retrograde axonal transport of transmitter enzymes, fructose labelled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes 1981; 30: 797-803.
25. Liuzzi FJ, Depto AS. Neuropathy: growth factors and nerve regeneration. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus. Phildelphia: Lippincott-Raven Publisher, 1996: 766-772.
26. Guy RJC, Richards F, Edmonds ME, Watkins PJ. Diabetic autonomic neuropathy and iritis: an association suggesting an immunological cause. Br Med J 1984; 289: 343-345.
27. Gilbey SG, Guy RJC, Jones H, Watkins PJ, Vergani D. Cell-mediated immunity and symptomatic diabetic neuropathy: an immunological association? Diabetic Med 1986; 3: 241-245.
28. Brown FM, Brink SJ, Freeman R, Rabinowe SL. Antisympathetic nervous system autoantibodies. Diminished catecholamines with orthostasis. Diabetes 1989; 38: 938-941.
29. Schnell O, Muhr D, Dresel S, Tatsch K, Ziegler AG, Haslbeck M, Standl E. Autoantibodies against sympathetic ganglia and evidence of cardiac sympathetic dysinnervation in newly diagnosed and long-term IDDM patients. Diabetologia 1996; 39: 970-975.
30. Duchen LW, Anjorin A, Watkins PJ, Mackay JD. Pathology of autonomic neuropathy in diabetes mellitus. Ann Intern Med 1980; 92: 301-303.
31. Anonymous. Diabetic neuropathy. Lancet 1989; i: 1113-1114.
32. Stevens MJ, Feldman EL, Greene DA. The aetiology of combined roles of metabolic and vascular defects. Diabetic Med 1995; 12: 566-579.
33. Boulton AJM, Ward JD. Diabetic neuropathies and pain. Clin Endocrinol Metab 1986; 15: 917-931.
34. Dyck PJ, Karnes J, Brian PC. Diagnosis, staging, and classification of diabetic neuropathy and associations with other complications. In: Dyke PJ, ed. Diabetic Neuropathy, London: WB Saunders Company 1987: 36-44.
35. Consensus Report. Standardized measures in diabetic neuropathy. Diabetes Care 1996; 19 (suppl. 1): 72-92.
36. Greene DA. Neuropathy: disease of the peripheral nerves and lesions of the feet. Diabetic Complications. Oxford: Oxford University Press, 1989; 66-96.
37. Thomas PK. Diabetic neuropathy: epidemiology and pathogenesis. In: Pickup J, Williams G, eds. Textbook of Diabetes. Oxford: Blackwell Scientific Publications, 1991: 613-622.
38. Assal J Ph. Epidemiology of diabetic peripheral neuropathy. Diab Res Clin Pract 1987; 2: 196-198.
39. Melton LJ, Dyck PJ. Clinical features of diabetic neuropathies-epidemiology. In: Dyck PJ, ed. Diabetic Neuropathy. London: WB Saunders Company, 1987: 27-35.
40. Veves S, Boulton AJM. Diabetic neuropathy: the diabetologist's view. In: Horrobin DF, ed. Treatment of Diabetic Neuropathy. Edinburgh: Churchill Livingstone, 1992: 1-10.
41. Dyck PJ, Buchek W, Spring EM, Karnes JL, Litchy WJ, O'Brian PC, Service P. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 1987; 10: 432-440.
42. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed. Diabetes Care 1978; 1: 168-188.
43. Dyck PJ, Karnes JL, O'Brian PC, Litchy WJ, Low PA, Melton LJ. The prevalence by staged severity of various types of diabetic neuropathy in a population based cohort: The Rochester Neuropathy Study. Neurology 1993; 43: 817-824.
44. Boulton AJM, Knight G, Drury J, Ward JD. The prevalence of symptomatic, diabetic neuropathy in an insulin treated population. Diabetes Care 1985; 8: 125-128.
45. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
46. Boulton AJM, McLeod AF, Williams DRR, Sonksen PH. The prevalence of diabetic neuropathy in patients attending UK hospital clinics. Diabetologia 1992; 34 (suppl. 12): A34.
47. Sönksen JM, Boulton AJM, Gardia MT, Ward JD, Skyler J. The association between symptomatic sensory neuropathy and body stature in diabetic patients. Diabetes Res Clin Pract 1988; 4: 95-98.
48. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Manjoo Q, Bass EB et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of diabetes complications study. Diabetes 1989; 38: 1456-1461.
49. Boulton A. What causes neuropathic pain: J Diab Compl 1992; 6: 58-63.
50. Asbury AK, Fields HL. Pain due to peripheral damage: a hypothesis. Neurology 1984; 34: 1587-1540.
51. Morley GM, Moordian AG, Levine AS, Morley JE. Mechanism of pain in diabetic peripheral neuropathy. Am J Med 1984; 77: 79-82.
52. Greene DA. Effects of aldose reductase inhibitors on the progression of nerve fibre damage in diabetic neuropathy. J Diab Compl 1992; 6: 35-38.
53. Jensen TS, Bach FW, Kastrup J, Dejgaard A, Brennum J. Vibratory and thermal thresholds in diabetics with and without clinical neuropathy. Acta Neurol Scand 1991; 84: 326-533.
54. Cameron NE, Leonard MB, Ross IS, Whiting PH. The effect of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin rat. Diabetologia 1986; 29: 168-174.
55. Vliet JA, Navaro X, Kennedy WR, Goetz FC, Suntherland. The effect of pancreas transplantation on diabetic polyneuropathy. Transplantation 1988; 45: 368-370.
56. Boulton AJM, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982; 5: 386-392.
57. Samanta A, Burden AC. Rapid improvements in pain of diabetic neuropathy. Pract Diabetes 1985; 2: 22-23.
58. Greene DA, Sima AF, Stevens J, Feldman EL, Killen PD, Henry DN et al. Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabete Metab 1993; 9: 189-217.
59. Christensen JEJ, Varnek L, Gregersen G. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double blind study. Acta Neurol Scand 1985; 71: 164-167.
60. Fagius J, Brattberg A, Jameson S, Berne C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 1985; 28: 323-329.
61. O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brian IAD, Corral RJM. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one years treatment with sorbinil. Diabetic Med 1988; 5: 537-542.
62. Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Haler E. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1990; 308: 898-908.
63. Sundquist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis S, Owens DR et al. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with Ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. J Diab Compl 1992; 6: 123-130.
64. Boulton AJM, Levin SR, Comstock JP. A multicenter trial of the aldose reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990; 33: 431-437.
65. Macleod AF, Boulton A, Owens DR, Van Roy P, Van Gerven JMA, Macrury S et al. A multicenter trial of the aldose reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. Diabete Metab 1992; 18: 14-20.
66. Gerven JMA, Lemkes HHPJ, Dijk JG. Long term effects of tolrestat on symptomatic diabetic sensory polyneuropathy. J Diab Compl 1992; 6: 45-48.
67. Santiago JV, Sonksen PH, Boulton AJM, MacLeod A, Bochenk W, Graepel GJ, Gonen B. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy. Effects on nerve function. J Diab Compl 1993; 7: 170-178.
68. Sima AAF, Greene DA, Brown MB, Hohman TC, Graepel GJ, Bohshenek WJ, Beg M. Effect of hyperglycaemia and the aldose reductase inhibitor tolrestat on sural nerve biochemestry and morphometry in advanced diabetic neuropathy. J Diab Compl 1993; 7: 157-169.
69. Sima AAF, Prashar A, Nathaniel V, Bril V, Werb MR, Greene DA. Overt diabetic neuropathy: repair of axoglial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Diabetic Med 1994; 10: 115-121.
70. Giugliano D, Marfella R, Quatraro A, Rosa N, Salvatorre T, Ozzolino D et al. Tolrestat for mild diabetic neuropathy. Ann Intern Med 1993; 118: 7-11.
71. Giugliano D, Acampora R, Marfella R, DiMaro G, Rosa N, Misso L et al. Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 1995; 18: 536-541.
72. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1982; 147: 1442-1444.
73. Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. J Am Med Assoc 1984; 251: 1727-1730.
74. Gomez-Perez FJ, Rull JA, Dies H, Rodriques-Rivera G, Gonzales-Barranco J, Lozanso CA. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double blind cross over study. Pain 1985; 23: 395-400.
75. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589-596.
76. Sindrup SH. Antidepressant in the treatment of diabetic neuropathy syndromes. Dan Med Bull 1994; 41: 66-78.
77. Sindrup SH, Bjerre U, Dejgaard A, Broesen K, Aaes-Joergensen T, Gram LF. The selective serotonin re-uptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-552.
78. Rull JA, Quiberra R, Millan HG, Lozano O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double blind cross-over study. Diabetologia 1969; 5: 215-218.
79. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic neuropathy:a double blind placebo-controlled trial. Diabetic Med 1990; 7: 319-323.
80. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. Ann Intern Med 1991; 151: 2225-2229.
81. Ziegler D, Hanefeld M, Ruhnau KJ, Meisner HP, Lobisch M, Schutte K, Gries FA. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alfa-lipoic acid. Diabetologia 1995; 38: 1425-1433.
82. Tsigos C, Gibson S, Crosby S, White A, Young RJ. Cerebrospinal fluid levels of beta-endomorphin in painful and painless diabetic polyneuropathy. J Diab Compl 1992; 9: 92-96.
83. Kastrup J, Petersen P, Dejgaard A, Angelo H, Hilsted J. Treatment of chronic diabetic neuropathy with intravenous lidocaine infusion. Br Med J 1986: 292: 173-174.
84. Dejgaard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; i: 9-11.
85. Imura M, Tominanga T, Yamada K. Clinical experience of mexiletine for chronic painful diabetic neuropathy. Jpn J Med Sci Biol 1990; 18: 93-99.
86. Ackerman WE, Colclough GW, Juneja MM, Bellinger K. The management of oral mexiletine and intravenous lidocaine to treat chronic painful symmetrical distal diabetic neuropathy. KMA Journal 1991; 89: 500-501.
87. Tanelian DL, Brose WG. Neuropathic pain can be relieved by drugs that use dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine. Anesthesiologiy 1991; 74: 949-951.
88. Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. J Diab Compl 1992; 15: 1550-1555.
89. Chabal C, Jacobsen L, Marino A, Chaney E, Britell CW. The use of oral mexiletine for the treatment of pain after nerve injury. Anesthesiology 1992; 76: 513-517.
90. Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM ef al. Highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993; 16: 1103-1115.
91. Ferrante FM, Paggiolij, Cherukuri S, Arthur GR. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg 1996; 82: 91-97.
92. Paggioli JJ, Gabor BR. Intravenous and oral anesthetics in pain management: reflections on intravenous lidocaine and mexiletine. Pain 1995; 5: 69-72.
93. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibres originating in rat sciatic neuromas. Pain 1989; 38: 333-338.
94. Bach F, Jensen T, Kastrup J, Stigsby B, Dejgaard A. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain 1990; 40: 29-34.
95. Jaffe R, Rowe MA. Subanesthetic concentrations of lidocaine selectively inhibit a nociceptive response in the isolated rat spinal cord. Pain 1995; 60: 167-174.
96. Woolf C, Hallin ZW. The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord. Pain 1985; 23: 361-374.
97. Kastrup J, Petersen P, Dejgaard A. Intravenous lidocaine and cerebral blood flow: impaired microvascular reactivity in diabetic patients. J Clin Pharmacol 1990; 30: 318-323.
98. Kastrup J, Bach FW, Petersen P, Dejgaard A, Ekman R, lensen S, Angelo H. Lidocaine treatment of painful diabetic neuropathy and endogenous opoid peptides in plasma. Clin J Pain 1989; 5: 239-244.
99. Ward J. Clinical aspects of diabetic somatic neuropathy. In: Pickup J, Williams G, eds. Textbook of Diabetes. Oxford: Blackwell Scientific Publications, 1991: 623-634.
100. Edmonds ME, Watkins PJ. Clinical presentations of diabetic autonomic neuropathy. In: Bannister R, Mathias CJ, eds. Autonomic Failure: a Textbook of Clinical Disorders of the Autonomie Nervous System. Oxford: Oxford Medical Publications, 1992: 698-720.
101. Lowe LP, Tranel D, Wallace RB, Welty TK. Type II diabetes and cognitive function. A population based study of native americans. Diabetes 1994; 17: 891-896.
102. Ziegler D, Guerci B, Algan M, Lonchamp P, Webwe M, Drouin P. Improved visual evoked potential latencies in poorly controlled diabetic patients after short-term strict metabolic control. Diabetes Care 1994; 17: 1141-1147.
103. Vinik AI, Holland MJ, Beau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care 1992; 15: 1926-1975.
104. Spallone V, Uccioli L, Meenzinger G. Diabetic autonomic neuropathy. Diabetic Med 1995; 3: 227-257.
105. Ziegler D, Dannehl K, Muhlen H, Spuler M, Gries FA. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabetic Med 1992; 9: 806-814.
106. Ziegler D, Gries FA, Spuler M, Lessmann L. The epidemiology of diabetic neuropathy. J Diab Compl 1992; 6: 49-57.
107. Neil HAW, Thomson AV, John S, McCarty ST, Mann JL. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabetic Med 1989; 6: 20-24.
108. Eurodiab IDDM Complication Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM complications study. Diabetologia 1994; 37: 278-285.
109. Edmonds ME, Watkins PJ. Autonomic Neuropathy. The Diabetes Annual 8. Barking: Elsevier Science, 1994: 389-405.
110. Dienfeld JE, Dagget PR, Harrison MJ. The role of diabetic autonomic neuropathy in diabetic foot ulceration. J Neurol Sci 1980; 47: 203-210.
111. Sampson MJ, Wilson S, Karagianis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin dependent diabetics. Q J Med 1990; 75: 635-646.
112. Brian IA, McFadden JP, Corral RJ. The influence of autonomic neuropathy on mortality in insulin dependent diabetes. Q J Med 1991; 79: 495-502.
113. Fagius J. Aspects of autonomie neurophysiology in diabetic polyneuropathy: A brief review. Diabet Med 1991; 8: 58-62.
114. Ziegler D. Diabetic cardiovascular autonomie neuropathy: prognosis, diagnosis and treatment. Diab Metab Rev 1994; 4: 339-383.
115. Ewing DJ. Non invasive evaluation of heart rate: the time domain. In: Low P, ed. Clinical Autonomic Disorders. Boston, MA: Little Brown and Co., 1993: 297-331.
116. Low P, Pfeifer M. Standardisation of clinical tests for practice and clinical trials. In: Low P, ed. Clinical Autonomic Failure. Boston, MA: Little Brown and Co., 1993: 287-297.
117. Cryer PE, Silverberg AB, Santiago JV, Shah SD. Plasma catecholamines in diabetes. The syndromes of hypoadrenergic and hyperadrenergic autonomic neuropathy. Am J Med 1978; 64: 407-416.
118. Floras J, Jones JV, Hassan O, Osikowska A, Sever PS, Sleight P. Failure of plasma norepinephrine to consistently reflect sympathetic activity in humans. Hypertension 1986; 8: 641-649.
119. Hilsted J, Christensen NJ, Madsbad S. Whole body clearance of norepinephrine. J Clin Invest 1983; 71: 500-505.
120. Christensen NJ, Degjaard A, Hilsted J. Plasma dihydrophenylglycol (DHPG) as an index of diabetic autonomic neuropathy. Clin Physiol 1988; 8: 577-580.
121. Hilsted J. Testing for autonomic failure. Ann Clin Res 1984; 16: 128-135.
122. Cannon WB, Rosenblueth A. The Supersensitivity of Denervated Structures. A Law of Denervation. New York: Macmillan, 1979.
123. Hilsted J Richter E, Madsbad S, Tronier B, Christensen EJ, Hildebrandt P, et al. Metabolic and cardiovascular responses to epinephrine in diabetic autonomic neuropathy. N Engl J Med 1987; 317: 421-426.
124. Dejgaard A, Andersen P, Hvidberg P, Hilsted J. Cardiovascular, metabolic, and hormonal responses to noradrenaline in diabetic patients with autonomic neuropathy. Diabetic Med 1996; 13: 983-389.
125. Bodmer CW, Schaper NC, Jannsen M, DeLeuw PW. Selective enhancement of alfa 2 adreneceptor mediated vasoconstriction in insulin dependent diabetic patients with microalbuminuria. Clin Sci 1995; 88: 421-426.
126. Moorhouse JA, Carter SA, Doupe J. Vascular responses in diabetic peripheral neuropathy. Br Med J 1986; 1: 883-888.
127. Scobie N, Rogers PT, Brown PM, Godfrey H, Soenksen PH. Supersensitivity to both tyramine and noradrenaline in diabetic autonomic neuropathy. J Neural Neurosurg Psychiatry 1987; 50: 275-280.
128. Bodmer C, Patrick A, How TV, Williams G. Exaggerated sensitivity to NE-induced vasoconstriction in IDDM patients with microalbuminuria. Diabetes 1992; 41: 209-214.
129. Polonsky RJ. Neuropharmacological investigation. In: Bannister R, Mathias CJ, eds. Autonomic Failure. Oxford: Oxford Medical publications. 1992: 334-358.
130. Bannister R, Davies B, Holly E, Rosenthal T, Sever P. Defective cardiovascular reflexes and supersensitivity to sympathomimetic drugs in autonomic failure. Brain 1979; 102: 163-176.
131. Eichler HG, Blaschke TF, Kraemer FB, Ford GA, Daum BB, Huffman BB. Responsiveness of superficial hand veins to alfa-adrenoceptor agonists in insulin-dependent diabetic patients. Clin Sci 1992; 82: 163-168.
132. Dejgaard A, Hilsted J, Henriksen JH, Christensen NJ. Plasma adrenaline kinetics in Type 1 (insulin dependent) diabetic patients with and without autonomic neuropathy. Diabetologia 1989; 32: 810-813.
133. Dejgaard A, Hilsted J, Christensen NJ. Noradrenaline and isoproterenol kinetics in patients with and without autonomic neuropathy. Diabetologia 1986; 29: 773-777.
134. Polonsky RJ, Goldstein DS, Brown RT, Keiser HR, Kopin IJ. Decreased sympathetic neuronal uptake in idiopathic orthostatic neuropathy. Ann Neurol 1985; 18: 48-53.
135. Hoeldtke RD, Cilmi KM. Norepinephrine secretion and production in diabetic autonomic neuropathy. J Clin Endocrinol Metab 1984; 59: 246-252.
136. Esler M, Jackman G, Bobik A, Kelleher G, Jennings P, Shevs LH, Korner P. Determination of norepinephrine apparent release rate and clearance in humans. Life Sci 1979; 25: 1461-1470.
137. Dejgaard A, Liggett SB, Christensen NJ, Cryer PE, Hilsted J. Adrenergic receptors are a fallible index of adrenergic denervation hypersensitivity. Scand J Clin Lab Invest 1991; 51: 659-666.
138. Liggett SB, Marker JC, Shah SD, Roper CL, Cryer PE. Direct relationship between mononuclear leukocyte and lung beta-adrenergic receptors and apparent reciprocal regulation of extravascular, but no intravascular alfa- and beta-adrenergic receptors by the sympathochromaffin system in humans. J Clin Invest 1988; 82: 48-56.
139. Liggett SB, Shah SD, Cryer PE. Human tissue adrenergic receptors are not predictive of response to epinephrine in vivo. Am J Physiol 1989; 256: E600-E609.
140. Wahrenberg H, Arner P, Adamsen U. Increased lipolytic sensitivity to catecholamines in diabetic patients with severe autonomic neuropathy. J Int Med 1993; 2276: 309-316.
141. Abrahm D, Hollingworth PJ, Smith CB, Zucker LB, Sobotka PA, Vinik A. Decreased alfa adrenergic receptors on platelet membranes from diabetic patients with autonomic neuropathy and ortostatic hypotension. J Clin Endocrinol Metab 1986; 63: 906-912.
142. Navarro X, Kennedy WR, Sutherland DER. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia 1991; 34: 108-112.
143. The St Thomas's Diabetes Study Group. Failure of improved glycaemic control to reverse diabetic autonomic neuropathy. Diabetic Med 1992; 2: 330-333.
144. Campell IW, Ewing DJ, Clarke BF. 9-alpha-fludrohydrocorticonein: the treatment of postural hypotension in diabetic autonomic neuropathy. Diabetes 1975; 24: 381-384.
145. Kuchel O, Buu NT, Gutskakowa J, Genest J. Treatment of severe orthostatic hypotension by metoclopramide. Ann Intern Med 1980; 93: 841-843.
146. Kochar MS, Itskowitz HD, Aolbers JW. Treatment of orthostatic hypotension with indomethacin. Am Heart J 1979; 98: 271-280.
147. Hoeldtke RD, O'Doriso TM, Boden C. Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995. Lancet 1986; 2: 602-605.
148. Onrot J, Goldberg MR, Biaggoni I, Hollister AS, Kincaid DEA. Haemodynamic and humoral effects of caffeine in autonomic failure therapeutic implications for postural hypotension. N Engl J Med 1985; 313: 549-554.
149. Jankovic J, Gilde JL, Hiner BC, Kaufman H, Brown DC, Coglan CH, Rubin M. Neurogenic orthostatic hypotension: a double blind, placebo-controlled study with midodrine. Am J Med 1993; 95: 38-48.
150. Man In't Veld AJ, Schalekamp MADH. Pindolol acts as beta-receptor agonist in orthostatic hypotension: therapeutic implications. Br Med J 1981; 282: 929-931.
151. Boesen F, Andersen EB, Kastrup J, Hesse B, Christensen NJ. Treatment of orthostatic hypotension with pindolol. Acta Neurol Scand 1982; 66: 386-391.
152. Dejgaard A, Hilsted J. No effect of pindolol on postural hypotension in Type 1 (insulin dependent) diabetic patients with autonomic neuropathy. A randomized double-blind controlled study. Diabetologia 1988; 31: 281-284.
153. McCall A. The impact of diabetes on the CNS. Diabetes 1992; 41: 557-570.
154. Kastrup J, Roersgaard S, Parving HH, Lassen NA. Impaired autoregulation of cerebral blood flow in long-term Type 1 diabetic patients with nephropathy and retinopathy. Clin Physiol 1986; 6: 549-559.
155. Biessel GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH. Cerebral function in diabetes mellitus. Diabetologia 1994; 37: 643-650.
156. Reske-Nielsen E, Lundbaek K, Rafaelsen OJ. Pathological changes in the central and peripheral nervous system of young long-term diabetics. Diabetologia 1965; 1: 233-244.
157. DeJong RN. The nervous system complications in diabetes mellitus with special reference to cerebrovascular changes. J Nerv Ment Dis 1950; 3: 181-206.
158. Mooridan AD. Diabetic complications of the central nervous system. Endocr Rev 1988; 9: 346-356.
159. Collier A, Mitchell JD, Clarke BF. Visual evoked potential and contrast sensitivity function in diabetic retinopathy. Br Med J 1985; 27: 248.
160. Uccioli L, Parisi V, Monticome G, Parisi L, Durola L, Pernini C, et al. Electrophysiological assessment of visual function in newly diagnosed IDDM. Diabetologia 1995; 38: 804-808.
161. Di Mario U, Morano S, Valle E, Pozzessere G. Electrophysiological alterations of the central nervous system in diabetes mellitus. Diabete Metab 1995; 3: 259-277.
162. Frost-Larsen K, Christensen JS, Parving HH. The effect of strict short-term metabolic control on retinal nervous system abnormalities in newly diagnosed Type 1 diabetic patients. Diabetologia 1983; 24: 207-209.
163. 1c in children with diabetes mellitus. Turk J Pediatr 1994; 36: 279-287.
164. Moreo G, Mariani E, Pizzamiglio G, Colucci GB. Visual evoked potentials in NIDDM: a longitudinal study. Diabetologia 1995; 38: 573-576.
165. Dejgaard A, Gade A, Larsson H, Balle V, Parving A, Parving HH. Evidence of diabetic encephalopathy. Diabetic Med 1991; 8: 162-167.
166. Donald MW, Williams DL, Surridge DHC, Monga TN, Lawson JS, Bird JS, Letemendia FJJ. Functional correlates of reduced central conduction velocity in diabetic subjects. Diabetes 1984; 33: 627-633.
167. Khardori R, Soler NG, Good DC, Devlesc H, Brougton D, Walbert J. Brainstem auditory - and visual - evoked potentials in Type 1 diabetic patients. Diabetologia 1986; 29: 362-365.
168. Fedele D, Martini A, Cardone C, Comacchio F, Bellavre F, Molinari G, Negrin P, Crepaldi G. Impaired auditory brainstem evoked responses in insulin dependent diabetic patients. Diabetes 1989; 33: 1085-1089.
169. Virtaniemi J, Laakso M, Karja J, Nuutinen J, Karjaleinen S. Auditory brainstem latencies in Type 1 diabetic patients. Am J Otolaryngol 1993; 14: 413-418.
170. Virtaniemi J, Kuusisto J, Karjalainen L, Laakso M. Improvement of metabolic control does not normalize auditory brainstem latencies in subjects with insulin dependent diabetes mellitus. Am J Otolaryngol 1995; 16: 172-176.
171. Staenninger E, Leissner L, Oman J. Brainstem auditory evoked potentials during hypoglycaemia in insulin-dependent diabetic children. Acta Paediatr 1994; 83: 1291-1295.
172. Lunetta M, Damanti AR, Fabri G, Lombardo M, Di Mauro M, Mughini L. Evidence by magnetic resonance imaging of cerebral alterations of atrophy type in young insulin-dependent diabetic patients. J Endocrinol Invest 1994; 17: 241-245.
173. Griffey H, Eaton P, Sibbitt RR, Sibbitt WL, Bicknell J. Diabetic neuropathy: structural analysis of nerve hydration by magnetic resonance spectroscopy. J Am Med Assoc 1988; 19: 2872-2878.
174. Larsson HBW, Frederiksen J, Petersen J. Assesment of demyelination, edema and gliosis by in vivo determination of T1 and T2 in the brain of patients with acute attack of multiple sclerosis. Magn Reson Med 1989; 11: 337-348.
175. Parving A, Elberling C, Balle V, Parbo J, Dejgaarcl A, Parving HH. Hearing disorders in patients with insulin dependent diabetes mellitus. Audiology 1990; 29: 113-121.
176. Miller JJ, Beck L, Davis A, Jones DE, Thomas AB. Hearing loss in patients with diabetic retinopathy. Am J Otolaryngol 1983; 4: 342-346.
177. Ferrer JP, Biurrum O, Lorente J, Conget J, Espana R, Esmatjes E, Gomis R. Auditory function in young patients with Type 1 diabetes mellitus. Diabetes Res Clin Pract 1991; 11: 17-22.
178. DCCT research group. Effects ot intensive diabetes therapy on neuropsychological function in adults in the diabetes control and complications trial. Ann intern Med 1996; 124: 379-388.
179. Lawson JS, Erdahl TN, Bird CE, Donald MW, Surriclge HC, Letemendia FJJ. Neuropsychological function in diabetic patients with neuropathy. Br J Psychiatry 1984; 145: 263-268.
180. Ryan CM, Williams TM, Orchard TJ, Finegold DN. Psychomotor slowing is associated with distal symmetrical polyneuropathy in adults with diabetes mellitus. Diabetes 1992; 41: 107-113.
181. Ryan CM, Williams TM, Finegold DN, Orchard TJ. Cognitive dysfunction in adults with Type 1 diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 1993; 36: 329-334.
182. Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995; 38: 1096-1102.